Moderate to Severe Rheumatoid ArthritisPhase 4ROCkIESNCT01927757
Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthritis Who Have Lost Response to Adalimumab
A Phase 4 study testing Etanercept and Methotrexate in people with Moderate to Severe Rheumatoid Arthritis, run by Amgen at 45 sites in 3 countries.
Trial summary
To evaluate the efficacy of etanercept in adults with moderate-to-severe rheumatoid arthritis (RA) who did not respond to or lost a satisfactory response to adalimumab when used as their first biologic agent. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Moderate to Severe Rheumatoid Arthritis
- What is being tested?
- Etanercept and Methotrexate
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 90 participants
- Where
- 45 sitesin 3 countries
- Study dates
- 6 May 2013to 11 Jun 2015
- Phase
- Phase 4
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Able to provide informed consent
- Diagnosed with moderate to severe rheumatoid arthritis for at least 6 months
- Active RA with at least 3 swollen and tender joints
- Failure to respond to a combination treatment of adalimumab and methotrexate (must have taken combination at least 3 months) or loss of a satisfactory response to the combination of adalimumab and methotrexate, which was taken for at least 6 months (if currently taking adalimumab must complete 2 weeks without it prior to starting study drug)
- Negative for hepatitis B and C
- Negative serum and urine pregnancy tests before starting study
Show all 9Show fewer
- currently taking (stable dose) 15 mg methotrexate weekly for at least 8 weeks/has been taking methotrexate for at least 12 weeks total - lower dose of 10 mg per week is permitted with documented intolerability
- Normal chest X-ray within 3 months
- Negative testing for tuberculosis (TB)
Who cannot join
- Class IV RA (wheel-chair or bed-bound)
- Significant concurrent medical conditions, including: (uncontrolled type 1 diabetes, poorly controlled type 2 diabetes, symptomatic heart failure, myocardial infarction in past year, history of unstable angina within past year, uncontrolled hypertension, severe chronic pulmonary disease, major chronic inflammatory or connective tissue disease other than RA, Multiple sclerosis, active malignancy, or history of cancer, alcoholic hepatitis or history of alcoholic liver disease)
- Other inclusion/exclusion criteria may apply
Trial locations and contacts
45 sites in 3 countries.
45 sites in 3 countries
United States32 sites
Research Site
Austin, Texas, 78731
Research Site
Battle Creek, Michigan, 49017
Research Site
Bowling Green, Kentucky, 42101
Research Site
Brandon, Florida, 33511
Research Site
Charlotte, North Carolina, 28210
Research Site
Chesapeake, Virginia, 23320
Research Site
Clarksburg, West Virginia, 26301
Research Site
Corpus Christi, Texas, 78404
Research Site
Covina, California, 91723
Research Site
Denver, Colorado, 80230
Research Site
Duncansville, Pennsylvania, 16635
Research Site
Dunedin, Florida, 34698
Research Site
Fall River, Massachusetts, 02720
Research Site
Hemet, California, 92543
Research Site
Hixson, Tennessee, 37343
Research Site
Houston, Texas, 77034
Research Site
Largo, Florida, 33774
Research Site
Lawrenceville, Georgia, 30046
Research Site
Lincoln, Nebraska, 68516
Research Site
Middleburg Heights, Ohio, 44130
Research Site
Murrieta, California, 92563
Research Site
Paducah, Kentucky, 42003
Research Site
Palm Harbor, Florida, 34684
Research Site
Roanoke, Virginia, 24016
Research Site
San Diego, California, 92108
Research Site
Scottsdale, Arizona, 85258
Research Site
Seattle, Washington, 98133
Research Site
Smithtown, New York, 11787
Research Site
Tampa, Florida, 33609
Research Site
Tuscaloosa, Alabama, 35406
Research Site
Victoria, Texas, 77901
Research Site
Victorville, California, 92395
Canada12 sites
Research Site
Burlington, Ontario, L7R 1E2
Research Site
Hamilton, Ontario, L8N 1Y2
Research Site
Mississauga, Ontario, L5M 2V8
Research Site
Montreal, Quebec, H2L 1S6
Research Site
Montreal, Quebec, H3T 1Y3
Research Site
Québec, Quebec, G1V 3M7
Research Site
Québec, Quebec, G1W 4R4
Research Site
Quispamsis, New Brunswick, E2E 4J8
Research Site
St. John's, Newfoundland and Labrador, A1A 5E8
Research Site
St. John's, Newfoundland and Labrador, A1C 5B8
Research Site
Toronto, Ontario, M5G 1X5
Research Site
Victoria, British Columbia, V8V 3P9
About this study
Official title: A Single Arm Trial to Evaluate the Efficacy of Etanercept in Moderate to Severe Rheumatoid Arthritis Patients Who Failed to Respond or Lost a Satisfactory Response to Treatment With Adalimumab When Used as Their First Biologic Agent
To evaluate the efficacy of etanercept in adults with moderate-to-severe rheumatoid arthritis (RA) who did not respond to or lost a satisfactory response to adalimumab when used as their first biologic agent.
- Conditions
- Moderate to Severe Rheumatoid Arthritis
- Being tested
- Etanercept, Methotrexate
- Keywords
- rheumatoid arthritis, etanercept, arthritis, adalimumab failure to respond, loss of response to adalimumab, ACR20, methotrexate, Swollen joints, tender joints
- Medical subject headings
- Arthritis, Rheumatoid, Arthritis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EtanerceptBiological
Also called Enbrel®
Administered by subcutaneous injection
MethotrexateDrug
Background methotrexate at least 15 mg weekly
| Study group | Role | What they receive |
|---|---|---|
| Etanercept | Experimental | Participants received etanercept 50 mg administered subcutaneously once a week with methotrexate for 24 weeks Receives: Biological: Etanercept; Drug: Methotrexate |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 12
A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 20% improvement in tender joint count; • ≥ 20% improvement in swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: o Patient Global Assessment of Joint Pain (measured on a 100 mm VAS); o Patient Global Assessment of Disease Activity (measured on a horizontal scale from 0 to 100); o Physician Global Assessment of Disease Activity (measured on a horizontal scale from 0 to 100); o Health Assessment Questionnaire - Disability Index (HAQ-DI) scale from 0 to 3, where zero represents no disability and three very severe, high-dependency disability; o C-reactive protein level.
Measured: Baseline and Week 12
Secondary outcomes (12)
Percentage of Participants With an ACR 20 Response at Week 12 by Anti-adalimumab Antibody Subgroup
A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 20% improvement in tender joint count; • ≥ 20% improvement in swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: o Patient Global Assessment of Joint Pain (measured on a 100 mm VAS); o Patient Global Assessment of Disease Activity (measured on a horizontal scale from 0 to 100); o Physician Global Assessment of Disease Activity (measured on a horizontal scale from 0 to 100); o Health Assessment Questionnaire - Disability Index (HAQ-DI) scale from 0 to 3, where zero represents no disability and three very severe, high-dependency disability; o C-reactive protein level.
Measured: Baseline and Week 12
Percentage of Participants With an ACR 20 Response at Week 12 by Response Failure Type Subgroup
A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 20% improvement in tender joint count; • ≥ 20% improvement in swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: o Patient Global Assessment of Joint Pain (measured on a 100 mm VAS); o Patient Global Assessment of Disease Activity (measured on a horizontal scale from 0 to 100); o Physician Global Assessment of Disease Activity (measured on a horizontal scale from 0 to 100); o Health Assessment Questionnaire - Disability Index (HAQ-DI) scale from 0 to 3, where zero represents no disability and three very severe, high-dependency disability; o C-reactive protein level.
Measured: Baseline and Week 12
Percentage of Participants With an ACR 20 Response at Week 24
A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 20% improvement in tender joint count; • ≥ 20% improvement in swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: o Patient Global Assessment of Joint Pain (measured on a 100 mm VAS); o Patient Global Assessment of Disease Activity (measured on a horizontal scale from 0 to 100); o Physician Global Assessment of Disease Activity (measured on a horizontal scale from 0 to 100); o Health Assessment Questionnaire - Disability Index (HAQ-DI) scale from 0 to 3, where zero represents no disability and three very severe, high-dependency disability; o C-reactive protein level.
Measured: Baseline and Week 24
Percentage of Participants With an ACR 50 Response at Weeks 12 and 24
A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 50% improvement in tender joint count; • ≥ 50% improvement in swollen joint count; and • ≥ 50% improvement in at least 3 of the 5 following parameters: o Patient Global Assessment of Joint Pain (measured on a 100 mm VAS); o Patient Global Assessment of Disease Activity (measured on a horizontal scale from 0 to 100); o Physician Global Assessment of Disease Activity (measured on a horizontal scale from 0 to 100); o Health Assessment Questionnaire - Disability Index (HAQ-DI) scale from 0 to 3, where zero represents no disability and three very severe, high-dependency disability; o C-reactive protein level.
Measured: Baseline and Weeks 12 and 24
Percentage of Participants With an ACR 70 Response at Weeks 12 and 24
A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 70% improvement in tender joint count; • ≥ 70% improvement in swollen joint count; and • ≥ 70% improvement in at least 3 of the 5 following parameters: o Patient Global Assessment of Joint Pain (measured on a 100 mm VAS); o Patient Global Assessment of Disease Activity (measured on a horizontal scale from 0 to 100); o Physician Global Assessment of Disease Activity (measured on a horizontal scale from 0 to 100); o Health Assessment Questionnaire - Disability Index (HAQ-DI) scale from 0 to 3, where zero represents no disability and three very severe, high-dependency disability; o C-reactive protein level.
Measured: Baseline and Weeks 12 and 24
Change From Baseline in Disease Activity Score 28-C-Reactive Protein (DAS28-CRP)
The DAS28-CRP is a composite score to measure disease activity in patients with rheumatoid arthritis, derived from the following variables:
- The number of swollen and tender joints assessed using the 28-joint count;
- C-reactive protein (CRP) level
- Patient's global assessment of disease activity assessed on a score from 0 to 100.
The DAS28-CRP score ranges from zero up to approximately ten. DAS28-CRP scores above 5.1 indicate high disease activity. A negative change from baseline indicates improvement.
Measured: Baseline and weeks 12 and 24
Percentage of Participants With DAS28-CRP Improvement of ≥ 1.2 Units From Baseline
The DAS28-CRP is a composite score to measure disease activity in patients with rheumatoid arthritis, derived from the following variables: • The number of swollen and tender joints assessed using the 28-joint count; • C-reactive protein (CRP) level • Patient's global assessment of disease activity assessed on a score from 0 to 100. The DAS28-CRP score ranges from zero up to approximately ten. DAS28-CRP scores above 5.1 indicate high disease activity.
Measured: Baseline and weeks 12 and 24
Percentage of Participants With DAS 28-CRP < 3.2
The DAS28-CRP is a composite score to measure disease activity in patients with rheumatoid arthritis, derived from the following variables: • The number of swollen and tender joints assessed using the 28-joint count; • C-reactive protein (CRP) level • Patient's global assessment of disease activity assessed on a score from 0 to 100. The DAS28-CRP score ranges from zero up to approximately ten. DAS28-CRP scores less than 3.2 are considered low disease activity.
Measured: Weeks 12 and 24
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI)
The HAQ-DI is a questionnaire on which participants are asked to rate their level of difficulty on daily activities (dressing and grooming, arising, eating, and walking) and personal abilities (hygiene, reach, grip, and activity) as well as their use of aids, devices, or help from another person for these activities and disabilities. Responses are scored from 0 indicating no difficulty to 3 indicating inability to perform a task in that area. The overall score is the average of each of the 8 category scores and ranges from 0 (no disability) to 3 (very severe, high-dependency disability).
Measured: Baseline and weeks 12 and 24
Change From Baseline in 36-item Short Form Health Survey (SF-36) at Week 12
The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses of each domain, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning.
Measured: Baseline and Week 12
Change From Baseline in 36-item Short Form Health Survey (SF-36) at Week 24
The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses of each domain, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning.
Measured: Baseline and Week 24
Work Productivity and Activity Impairment (WPAI)
This 6-item assessment measures productivity losses during the past 7 days and includes measures on work time missed due to health, impairment while working due to health (the participant's assessment of the degree to which health affected their productivity while working), overall work impairment due to health (takes into account both hours missed due to health and the participant's assessment of the degree to which health affected their productivity while working) and activity impairment due to health (the degree in which health problems affected their ability to do regular daily activities). Scores for each measure are expressed from 0 to 100 with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes.
Measured: Baseline, week 12 and week 24
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Aug 2013 (estimated)
- Study start6 May 2013
- Primary completion11 Jun 2015
- Study completion11 Jun 2015
Why it stopped: Business decision due to slow enrollment
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Moderate to Severe Rheumatoid ArthritisStudies of the same condition, open and under way.
- More trials run by AmgenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 90 participants (actual)
Sponsor and investigators
- Lead sponsor
- Amgen
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- MD, Study director, Amgen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01927757
- Sponsor's protocol ID
- 20120125
- Acronym
- ROCkIES
- Status last verified
- Jan 2018
- First submitted
- 5 Jun 2013
- Last updated
- 30 Jan 2018
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Publications
Bessette L, Khraishi M, Kivitz AJ, Kaliyaperumal A, Grantab R, Poulin-Costello M, Isaila M, Collier D. Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment. Rheumatol Ther. 2017 Dec;4(2):391-404. doi: 10.1007/s40744-017-0079-x. Epub 2017 Sep 12.
PubMed 28900875
Study at a glance
From the registry record, last updated by the sponsor on 30 Jan 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Single Arm Trial to Evaluate the Efficacy of Etanercept in Moderate to Severe Rheumatoid Arthritis Patients Who Failed to Respond or Lost a Satisfactory Response to Treatment With Adalimumab When Used as Their First Biologic Agent
- ClinicalTrials.gov ID
- NCT01927757
- Acronym / sponsor ID
- ROCkIES / 20120125
- Conditions
- Moderate to Severe Rheumatoid Arthritis
- Keywords
- rheumatoid arthritis, etanercept, arthritis, adalimumab failure to respond, loss of response to adalimumab, ACR20, methotrexate, Swollen joints
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Business decision due to slow enrollment
- Enrolment
- 90 participants (actual)
- Lead sponsor
- AmgenIndustry (pharma, biotech, devices)
- Study start
- 6 May 2013 (actual)
- Primary completion
- 11 Jun 2015 (actual)
- Study completion
- 11 Jun 2015 (actual)
- First posted
- 23 Aug 2013 (estimated)
- Results
- Posted 11 Jul 2016
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To evaluate the efficacy of etanercept in adults with moderate-to-severe rheumatoid arthritis (RA) who did not respond to or lost a satisfactory response to adalimumab when used as their first biologic agent.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Etanercept | Experimental | Biological: Etanercept, Drug: MethotrexateParticipants received etanercept 50 mg administered subcutaneously once a week with methotrexate for 24 weeks |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Able to provide informed consent
- Diagnosed with moderate to severe rheumatoid arthritis for at least 6 months
- Active RA with at least 3 swollen and tender joints
- Failure to respond to a combination treatment of adalimumab and methotrexate (must have taken combination at least 3 months) or loss of a satisfactory response to the combination of adalimumab and methotrexate, which was taken for at least 6 months (if currently taking adalimumab must complete 2 weeks without it prior to starting study drug)
- Negative for hepatitis B and C
Key exclusion criteria (3 listed)
- Class IV RA (wheel-chair or bed-bound)
- Significant concurrent medical conditions, including: (uncontrolled type 1 diabetes, poorly controlled type 2 diabetes, symptomatic heart failure, myocardial infarction in past year, history of unstable angina within past year, uncontrolled hypertension, severe chronic pulmonary disease, major chronic inflammatory or connective tissue disease other than RA, Multiple sclerosis, active malignancy, or history of cancer, alcoholic hepatitis or history of alcoholic liver disease)
- Other inclusion/exclusion criteria may apply
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| EtanerceptAlso: Enbrel®Administered by subcutaneous injection | Biological | Etanercept |
| MethotrexateBackground methotrexate at least 15 mg weekly | Drug | Etanercept |
Primary outcome
Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 12
Time frame: Baseline and Week 12
A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 20% improvement in tender joint count; • ≥ 20% improvement in swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: o Patient Global Assessment of Joint Pain (measured on a 100 mm VAS); o Patient Global Assessment of Disease Activity (measured on a horizontal scale from 0 to 100); o Physician Global Assessment of Disease Activity (measured on a horizontal scale from 0 to 100); o Health Assessment Questionnaire - Disability Index (HAQ-DI) scale from 0 to 3, where zero represents no disability and three very severe, high-dependency disability; o C-reactive protein level.
12 secondary outcomes
Percentage of Participants With an ACR 20 Response at Week 12 by Anti-adalimumab Antibody Subgroup
Time frame: Baseline and Week 12
Percentage of Participants With an ACR 20 Response at Week 12 by Response Failure Type Subgroup
Time frame: Baseline and Week 12
Percentage of Participants With an ACR 20 Response at Week 24
Time frame: Baseline and Week 24
Percentage of Participants With an ACR 50 Response at Weeks 12 and 24
Time frame: Baseline and Weeks 12 and 24
Percentage of Participants With an ACR 70 Response at Weeks 12 and 24
Time frame: Baseline and Weeks 12 and 24
Change From Baseline in Disease Activity Score 28-C-Reactive Protein (DAS28-CRP)
Time frame: Baseline and weeks 12 and 24
Percentage of Participants With DAS28-CRP Improvement of ≥ 1.2 Units From Baseline
Time frame: Baseline and weeks 12 and 24
Percentage of Participants With DAS 28-CRP < 3.2
Time frame: Weeks 12 and 24
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI)
Time frame: Baseline and weeks 12 and 24
Change From Baseline in 36-item Short Form Health Survey (SF-36) at Week 12
Time frame: Baseline and Week 12
Change From Baseline in 36-item Short Form Health Survey (SF-36) at Week 24
Time frame: Baseline and Week 24
Work Productivity and Activity Impairment (WPAI)
Time frame: Baseline, week 12 and week 24
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jan 2018.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Background: PubMed 28900875Bessette L, Khraishi M, Kivitz AJ, Kaliyaperumal A, Grantab R, Poulin-Costello M, Isaila M, Collier D. Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment. Rheumatol Ther. 2017 Dec;4(2):391-404. doi: 10.1007/s40744-017-0079-x. Epub 2017 Sep 12.
- AmgenTrials clinical trials websiteLink provided by the sponsor.
Related trials for Moderate to Severe Rheumatoid Arthritis
Active, not recruitingPhase 3
Nipocalimab in Moderate to Severe Sjogren's Disease
Sjogrens Syndrome
Not yet recruitingPhase 2
Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid Arthritis
Rheumatoid Arthritis
Active, not recruitingObservational study
Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis
Rheumatoid Arthritis
RecruitingPhase 2
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
Rheumatoid Arthritis
RecruitingObservational study
A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING
Moderate to Severe Rheumatoid Arthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
MD study director
Amgen
45 sites in 3 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Etanercept and Methotrexate in people with Moderate to Severe Rheumatoid Arthritis, run by Amgen at 45 sites in 3 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 30 Jan 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 45 sites in United States, Canada, Puerto Rico. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 11 Jul 2016). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 12 (time frame: Baseline and Week 12). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01927757, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jan 2018.